Imagine trying to grow a rainforest plant in a small plastic pot; it just won't survive because the environment is wrong. Most gut bacteria are the same—they refuse to grow in standard lab dishes because they miss the complex slime and oxygen levels of the human body. This technology creates a high-tech 'fake mucus' gel that tricks these stubborn bacteria into growing, allowing scientists to study them for the first time.
Microbiome research is stalled because most gut bacteria cannot be grown in standard labs. This prevents the development of drugs for the 90% of diseases linked to microbiome imbalance.
A biomimetic 3D in vitro mucus-based platform called i-Mu3Gel® (commercialized as Gut3Gel) that mimics human oxygen and nutrient gradients.
If you are a drug discovery firm dealing with the inability to test new antibiotics on live gut microbes—this project developed the Gut3Gel platform that allows the growth of unculturable bacteria to accelerate the discovery of new treatments.
If you are a biotech SME dealing with inaccurate animal testing results—this project developed a biomimetic 3D substrate that mimics human mucus to provide more predictive, non-animal testing methodologies.
If you are a CRO dealing with low reproducibility in microbiome studies—this project developed a ready-to-use in vitro solution that recreates native oxygen and nutrient gradients for stable microbial growth.
Based on available project data, specific pricing is not disclosed, but the project focused on translating the technology into market-ready products for industrial sale.
Yes, the project specifically demonstrated the robustness and scalability of the Bac3Gel platform through validation in real-world research environments.
The project has resulted in a commercialized product known as Gut3Gel (i-Mu3Gel®), indicating proprietary technology developed by BAC3GEL, LDA.
The platform supports the adoption of New Approach Methodologies (NAMs) to reduce animal experimentation, which aligns with European regulatory priorities.
The project delivered a 'ready-to-use' in vitro solution, suggesting it can be integrated into industrial R&D teams without extensive custom setup.
The project is led by a single Portuguese SME (BAC3GEL, LDA.), resulting in a 100% industry ratio. This lean structure indicates a direct focus on commercialization and rapid market entry rather than academic exploration.
Contact BAC3GEL, LDA. in Portugal for Gut3Gel procurement.
Contact us to find similar biomimetic substrates for your R&D pipeline.
